



TGA public consultation on 'low risk' product regulation

Mary Malek (3rd year BBiomedSc student)
School of Public Health

Vic Skeptics Café Presentation, November 19, 2018



TGA consultation on 'low risk' product regulation

MMDR review released (2015)¹

TGA review of 'low risk' product regulation (2016-2017)²

- Ear candles and homeopathic products selected for analysis
- Public consultation held (> 1000 submissions received)

Government decided on regulatory reform (June 2018)²



References

1. Australian Government Department of Health. Expert Review of Medicines and Medical Devices Regulation [Internet]. Canberra ACT: Australian Government Department of Health; [date unknown] [updated 2017 March 16; cited 2018 Oct 19]. Available from: <http://www.health.gov.au/internet/main/publishing.nsf/content/expert-review-of-medicines-and-medical-devices-regulation>

2. Therapeutic Goods Administration. The future regulation of low risk products [Internet]. Symonston ACT: Therapeutic Goods Administration; 2018 June 21 [updated 2018 Oct 16; cited 2018 Oct 16]. Available from: <http://www.tga.gov.au/future-regulation-low-risk-products>



TGA consultation on 'low risk' product regulation

Ear candles¹

Option 1: Status quo regulation

Option 2: Exemption

Option 3: Exclusion



Homeopathic products¹

Option 1: Status quo regulation

Option 2: More scientific evidence

Option 3: Exemption

Option 4: Exclusion



References

1. Therapeutic Goods Administration. Consultation: Options for the future regulation of "low risk" products [Internet]. Symonston ACT: Therapeutic Goods Administration; March 2017 [cited 2018 Oct 06]. 68 p. Available from: <http://www.tga.gov.au/sites/default/files/consultation-options-future-regulation-low-risk-products.pdf>

Research aims and hypothesis

Aims:

1. Assess consultation submissions addressing ear candles and homeopathic products
2. Determine their impact on TGA/Government decision-making about regulatory reform

Hypothesis:


Consultation submissions were not taken into account in decision-making

Methods: Document analysis

1. Downloaded published submissions
2. Quantified them according to product(s) addressed, Option(s) supported and author identity
3. Extracted themes and illustrative quotations
4. Determined consensus regulatory actions based on submissions
5. Compared these to TGA/Government decisions and determined impact of submissions on decision-making



Overview of submissions



References

1. Therapeutic Goods Administration. The future regulation of low risk products [Internet]. Symonston ACT: Therapeutic Goods Administration; 2018 June 21 [updated 2018 Oct 16, cited 2018 Oct 16]. Available from: <http://www.tga.gov.au/future-regulation-low-risk-products>

Submissions addressing ear candles

- **Consensus regulatory action:** Option 1 (maintain status quo)
 - Supported by 7 of 13 (54%) authors
 - Including ACCC, NICM, FSM
 - Argued that continued specialist regulation by TGA is ideal
- **TGA/Government decision:** Option 3 (exclusion)¹
 - Concerns in submissions not addressed
 - 'Cutting red tape' agenda prioritised



References

1. Therapeutic Goods Administration. The future regulation of low risk products [Internet]. Symonston ACT: Therapeutic Goods Administration; 2018 June 21 [updated 2018 Oct 16, cited 2018 Oct 16]. Available from: <http://www.tga.gov.au/future-regulation-low-risk-products>

Submissions addressing homeopathic products

- **Consensus regulatory action:** Option 1 (maintain status quo)
 - Supported by 686 of 714 (81%) authors
 - Including ACCC, ARoH, AHA, FSM
 - Argued that continued specialist regulation by TGA is ideal
- **TGA/Government decision:** No decision made¹
 - Concerns in submissions not addressed
 - Regulatory paralysis



References


1. Therapeutic Goods Administration. The future regulation of low risk products [Internet]. Symonston ACT: Therapeutic Goods Administration; 2018 June 21 [updated 2018 Oct 16, cited 2018 Oct 16]. Available from: <http://www.tga.gov.au/future-regulation-low-risk-products>

Limitations and future directions

- **Limitations:**
 - Not all submissions published
 - Unclear whether organisations should be given more weight than individuals
- **Future directions:**
 - Analysis of other TGA consultations
 - Similar results found for consultation on pre-approval of advertisements

Conclusions

- Appears that consultation submissions **not** taken into account
- Implications for consumer protection and value of the consultation



The screenshot shows the Australian Government Department of Health Therapeutic Goods Administration website. The main heading is "Consultation: Options for the future regulation of 'low risk' products". A large blue question mark is overlaid on the page. The page indicates that the consultation closed on 12 May 2017. Below this, there is an "Invitation to comment" section stating: "The TGA sought comments from interested parties on the options for the future regulation of 'low risk' products." The page also includes a "Related information" section with links to "The future regulation of low risk products" and "Submissions received: Options for the future regulation of low risk products".